PDF(Pubmed)
Abstract：
Introduction The intertwined nature of obesity and diabetes, termed diabesity, is a significant health concern. Aspirin has been recognized for its potential in mitigating inflammation-related health issues, a key concern in managing diabesity. However, the optimal aspirin dosage and its impact on specific inflammatory markers, viz. high-sensitivity C-reactive protein (hs-CRP) and interleukin (IL)-6, over time remain a subject of ongoing research. Objective This study investigated the effects of different doses of aspirin (150mg and 300mg) on the levels of hs-CRP and IL-6 over a period of 6 months. Methods This cross-sectional observational quasi-experiment study involved 125 confirmed type-2 diabetes mellitus (T2DM) patients with obesity aged ≥40 years. Blood samples were collected for analyzing hs-CRP and IL-6 levels. Demographics and clinical characteristics, such as BMI, waist-hip ratio, blood parameters, fasting blood sugar (FBS), and hs-CRP, were analyzed. Results At baseline, both the 150 mg and 300 mg aspirin dose groups had similar median levels of hs-CRP. After two months, there was no significant difference (p=0.150). However, by six months, the 150mg dose group had a significantly higher median hs-CRP than the 300 mg dose group (p=0.003). The 150 mg dose group had a significantly higher median level of IL-6 levels at baseline (median; 40.0) compared to the 300 mg dose group (median; 2.27, p<0.0001). After two months, the levels of IL-6 in both groups were similar (median; 2.27 and 2.23 respectively, p<0.0001). By the end of six months, the groups had no significant difference (median; 0.53 and 2.22 respectively, p=0.128). Conclusion The dose of aspirin may significantly impact the levels of hs-CRP and IL-6 over time, with the effects being more pronounced after six months of treatment. These findings suggest that aspirin, a commonly used and cost-effective medication, could potentially be leveraged in a more targeted manner to manage inflammation (CRP and IL-6 levels) in individuals with diabesity.
摘要：
导言肥胖和糖尿病交织在一起，称为糖尿病，是一个重大的健康问题。阿司匹林因其在缓解炎症相关健康问题方面的潜力而被认可。管理糖尿病的一个关键问题。然而,阿司匹林的最佳剂量及其对特定炎症标志物的影响，viz.随着时间的推移,高敏C反应蛋白(hs-CRP)和白细胞介素(IL)-6仍然是一个正在进行研究的课题.目的研究不同剂量阿司匹林(150mg和300mg)在6个月内对hs-CRP和IL-6水平的影响。方法本横断面观察性准实验研究纳入125例确诊的2型糖尿病（T2DM）肥胖患者，年龄≥40岁。收集血样用于分析hs-CRP和IL-6水平。人口统计学和临床特征，比如BMI,腰臀比,血液参数,空腹血糖（FBS），和hs-CRP，进行了分析。结果在基线，150mg和300mg阿司匹林剂量组的hs-CRP中位数水平相似.两个月后,差异无统计学意义(p=0.150)。然而,六个月后，150mg剂量组的hs-CRP中位数显著高于300mg剂量组(p=0.003).与300mg剂量组(中位数;2.27,p<0.0001)相比,150mg剂量组具有在基线时显著更高的IL-6水平的中位数水平(中位数;40.0)。两个月后,两组的IL-6水平相似(中位数分别为2.27和2.23,p<0.0001)。六个月后，两组无显著差异(中位数；分别为0.53和2.22，p=0.128）。结论阿司匹林剂量对血清hs-CRP和IL-6水平有显著影响。治疗六个月后效果更加明显。这些发现表明阿司匹林，一种常用且具有成本效益的药物，可能以更有针对性的方式利用来管理糖尿病患者的炎症（CRP和IL-6水平）。
